ML133 HCl: Precision Inhibition of Kir2.1 in Pulmonary Research

Introduction: The Imperative for Selective Kir2.1 Inhibition

Ion channels are central to cellular excitability, homeostasis, and disease pathogenesis. Among these, the Kir2.1 potassium channel (encoded by KCNJ2) stands out for its pivotal role in regulating membrane potential and vascular smooth muscle cell physiology. Aberrant Kir2.1 activity has been implicated in pathological vascular remodeling, particularly in pulmonary hypertension (PH), where pulmonary artery smooth muscle cell (PASMC) proliferation and migration drive disease progression [source_type: paper][source_link: DOI]. Until recently, a lack of potent, selective inhibitors constrained the resolution of mechanistic studies. ML133 HCl, now available from APExBIO, addresses this challenge by offering high specificity and reliable performance in experimental settings [source_type: product_spec][source_link: URL].

Mechanism of Action: How ML133 HCl Targets Kir2.1 Channels

ML133 HCl is a small-molecule potassium channel inhibitor chemically identified as 1-(4-methoxyphenyl)-N-(naphthalen-1-ylmethyl)methanamine hydrochloride. Its selectivity is defined by an IC₅₀ of 1.8 μM at pH 7.4 and 290 nM at pH 8.5 for Kir2.1, while showing negligible inhibition of Kir1.1 and only weak effects on Kir4.1 and Kir7.1 channels [source_type: product_spec][source_link: URL]. This unique pharmacological profile is critical for dissecting the discrete physiological and pathological contributions of Kir2.1 without off-target interference.

Reference Insight Extraction: Core Findings and Their Assay Impact

The seminal investigation by Cao et al. (2022) advanced the field by directly linking Kir2.1 activity to PASMC proliferation and migration in both in vivo and in vitro models. By employing ML133 HCl as a selective Kir2.1 inhibitor, the authors demonstrated that pharmacological blockade of Kir2.1 reverses the proliferative and migratory effects induced by PDGF-BB stimulation in human PASMCs. This reversal was mechanistically associated with the suppression of OPN and PCNA expression and inhibition of the TGF-β1/SMAD2/3 pathway. The study's practical innovation lies in validating ML133 HCl as a tool compound for faithfully recapitulating and interrupting disease-relevant signaling cascades. For assay developers, this means ML133 HCl can be used to isolate Kir2.1-specific contributions in multifactorial cellular environments, providing a critical control for target validation and pathway mapping [source_type: paper][source_link: DOI].

Protocol Parameters

• assay: IC₅₀ for Kir2.1 inhibition | value_with_unit: 1.8 μM (pH 7.4), 290 nM (pH 8.5) | applicability: Kir2.1 functional blockade in vitro | rationale: Ensures selective channel inhibition at physiologically relevant pH | source_type: product_spec [source_link: URL]
• assay: Solubility in DMSO | value_with_unit: ≥15.7 mg/mL | applicability: Stock preparation for cell-based assays | rationale: Enables high-concentration stock solutions for accurate dosing | source_type: product_spec [source_link: URL]
• assay: Storage temperature | value_with_unit: -20°C (solid) | applicability: Long-term compound stability | rationale: Preserves chemical integrity and bioactivity | source_type: product_spec [source_link: URL]
• assay: In vitro pre-treatment | value_with_unit: 24 h (with ML133 HCl before growth factor addition) | applicability: PASMC proliferation/migration assays | rationale: Mirrors workflow in reference study for reproducible results | source_type: paper [source_link: DOI]
• assay: Solubility in ethanol | value_with_unit: ≥2.52 mg/mL (with gentle warming/ultrasonication) | applicability: Alternate solvent use | rationale: Provides flexibility in protocol design | source_type: product_spec [source_link: URL]
• assay: Long-term solution storage | value_with_unit: Not recommended | applicability: Assay planning | rationale: Ensures maximal activity by preparing fresh solutions | source_type: product_spec [source_link: URL]

Comparative Analysis: ML133 HCl in Context of Alternative Strategies

While the literature recognizes ML133 HCl as the gold standard for Kir2.1 inhibition, previous reviews, such as this detailed summary, concentrate on the compound's broad selectivity and its established role in cardiovascular modeling. Our analysis diverges by focusing on the workflow-critical parameters that enable reproducibility and on the translational significance of the TGF-β1/SMAD2/3 axis modulation. Unlike the visionary outlook presented here, which projects future clinical applications, this article remains tightly anchored in the implications of assay precision, compound handling, and the direct mechanistic insights derived from recent molecular medicine research.

Advanced Applications in Pulmonary Hypertension and Vascular Remodeling

ML133 HCl's selectivity for Kir2.1 positions it as a powerful tool in pulmonary artery smooth muscle cell proliferation research. The compound's ability to reverse pathological PASMC phenotypes, as validated by Cao et al., underscores its value in preclinical modeling of pulmonary vascular remodeling and PH. By precisely controlling the Kir2.1 channel's activity, researchers can now dissect the downstream effects on OPN, PCNA, and TGF-β1/SMAD2/3 signaling, facilitating the identification of new intervention points in cardiovascular ion channel research [source_type: paper][source_link: DOI].

Furthermore, unlike the approaches detailed in other reviews that emphasize ML133 HCl's utility for general disease modeling, this article empowers researchers with practical, source-backed recommendations for optimizing experimental conditions and interpreting Kir2.1-specific effects in complex signaling environments.

Quality Assurance and Data Integrity: What Sets APExBIO’s ML133 HCl Apart?

Every batch of ML133 HCl from APExBIO is supplied at ≥98% purity, with comprehensive quality control documentation (HPLC, NMR, and MSDS) [source_type: product_spec][source_link: URL]. This level of transparency underpins experimental reproducibility and regulatory compliance. The product’s robust solubility in DMSO and ethanol ensures compatibility with diverse assay platforms, while the detailed documentation streamlines workflow integration and troubleshooting.

Conclusion and Future Outlook

ML133 HCl has redefined the standards for selective potassium channel inhibition in cardiovascular and pulmonary research. The recent molecular medicine advances, particularly the elucidation of the Kir2.1–TGF-β1/SMAD2/3 axis in PASMC proliferation and migration, highlight the compound’s value as a precision tool for both fundamental and translational studies [source_type: paper][source_link: DOI]. By integrating rigorous assay parameters and leveraging high-purity materials from APExBIO, researchers can confidently advance the mechanistic dissection of potassium ion transport and its disease implications. As research continues to clarify Kir2.1’s specific roles, ML133 HCl will remain indispensable for protocol optimization and for bridging molecular insights to therapeutic hypotheses.